Avidity

Novartis investors turn spotlight on M&A after trial setbacks

Novartis shares dropped 11% following a late-stage trial failure for drug del-desiran, sparking investor concerns over its M&A strategy and $12 billion Avidity acquisition amid patent expiry challenge